Myelofibrosis Market is Expected to Grow at a CAGR of 7.3% by 2032 | DelveInsight

News provided by

Dec 19, 2022, 10:30 ET

The myelofibrosis market is expected to grow at a faster rate due to increased awareness and increase in novel discoveries. The expected launch of potential emerging therapies will boost the myelofibrosis market during the forecast period (2022–2032) in the 7MM.

LAS VEGAS, Dec. 19, 2022 /PRNewswire/ -- DelveInsight's Myelofibrosis Market Insights report includes a comprehensive understanding of current treatment practices, myelofibrosis emerging drugs, market share of individual therapies, and historical, current as well as forecasted myelofibrosis market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan].

Key Takeaways from the Myelofibrosis Market Report

As per DelveInsight analysis, the myelofibrosis market size in the 7MM was approximately USD 1,404 million in 2021.
According to the assessment done by DelveInsight, the estimated total myelofibrosis prevalent population in the 7MM was approximately 39.7K in 2021.
Leading myelofibrosis companies such as Geron Corporation, AbbVie, Sierra Oncology, Kartos Therapeutics, Menarini Group, Telios Pharma, Novartis Pharmaceuticals, NS Pharma, Karyopharm Therapeutics, Incyte Corporation, Bristol Myers Squibb, MorphoSys, Imago BioSciences, Roche, and others are developing novel myelofibrosis drugs that can be available in the myelofibrosis market in the upcoming years.
The myelofibrosis therapies in the pipeline include Momelotinib, Navitoclax, Parsaclisib, Reblozyl, Pelabresib, Bomedemstat, Selinexor, Navtemadlin and others.
The myelofibrosis market size is expected to increase owing to the increase in the prevalent population of myelofibrosis patients in the 7MM.
In August 2022, FDA accepted the New Drug Application (NDA) for GSK's Momelotinib for the treatment of myelofibrosis.
In May 2022, Selinexor, a first-in-class oral XPO1 inhibitor, was given the orphan drug designation by FDA for the treatment of myelofibrosis.

Discover which therapies are expected to grab major myelofibrosis market share @ Myelofibrosis Market Report

Myelofibrosis Overview

Myelofibrosis is a disorder in which normal bone marrow tissue is gradually replaced with a fibrous scar-like material. It is classified as a type of chronic leukemia and belongs to a group of blood disorders called myeloproliferative diseases. Over time, this leads to progressive bone marrow failure. Under normal conditions, the bone marrow provides a fine network of fibers on which the stem cells can divide and grow. Specialized cells in the bone marrow, known as fibroblasts, make these fibers. Myelofibrosis can be of two types: Primary myelofibrosis and Secondary myelofibrosis.

Primary myelofibrosis (also called chronic idiopathic myelofibrosis, agnogenic myeloid metaplasia) develops independently due to certain genetic mutations. It occurs most often between the ages of 50 and 70 years, mostly in men.

Secondary myelofibrosis occurs due to other disorders, particularly other blood disorders such as chronic myeloid leukemia, polycythemia vera, thrombocythemia, multiple myeloma, and lymphoma.

Initially, most people with primary myelofibrosis have no signs or symptoms. Eventually, myelofibrosis causes a reduction in the number of red blood cells, white blood cells, and platelets. A shortage of red blood cells (anemia) often causes extreme tiredness (fatigue) or shortness of breath. A loss of white blood cells can lead to an increased number of infections, and a reduction of platelets can cause easy bleeding or bruising.

The most common myelofibrosis symptoms are abdominal pain, swelling or mass in the abdomen, nausea, vomiting, loss of appetite and feeling full, weight loss, difficulty swallowing, and brisk bleeding. Myelofibrosis diagnosis is typically based on a patient's medical history, a thorough physical examination, and the results of a battery of tests. The testing methods used to confirm or rule out GIST vary depending on the myelofibrosis symptoms of the patient and other individual factors.

Myelofibrosis Epidemiology Segmentation

DelveInsight estimates that there were approximately 39.7K myelofibrosis prevalent cases in the 7MM in 2021. Among the EU5 countries, Germany had the highest myelofibrosis prevalent cases in 2021.

The myelofibrosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalent Cases
Total Diagnosed Prevalent Cases
Type-specific Prevalent Cases
Age-specific Prevalent Cases
Myelofibrosis Cases Based on Risk Stratification
Myelofibrosis Cases Based on Molecular Alterations
Treatment Eligible Pool
Transplant Eligible/Ineligible Cases

Download the report to understand which factors are driving myelofibrosis epidemiology trends @ Myelofibrosis Epidemiological Insights

Myelofibrosis Treatment Market

There is no such persisting therapy that has a promising permanent cure. The sole cure for myelofibrosis existing is allogeneic stem cell transplantation, but the therapy has its downsides. It is proven to be risky when administered to older patients or patients with preexisting medical complexities.

As myelofibrosis primarily affects older adults, stem cell transplantation is not a treatment option for most myelofibrosis patients. For most people with myelofibrosis, the cure is aimed at controlling disease symptoms and complications, enhancing the quality of life, and extending survival.

For patients with mild symptoms, drugs for myelofibrosis treatment include Ruxolitinib (Jakafi) and Interferon alfa (Intron A, Roferon-A, and Pegasys). Patients at high risk can be given treatment options like Pacritinib (Vonjo), Ruxolitinib (Jakafi), Fedratinib (Inrebic), and allogeneic hematopoietic stem-cell transplantation (HSCT).

Allogeneic HSCT is the only potentially curative therapy for myelofibrosis. Despite several improvements, outcomes of HSCT are still burdened by substantial morbidity and high transplant-related mortality.

Blood transfusions are recommended for anemia patients with myelofibrosis symptoms. Blood transfusions can increase a patient's RBC count and ease symptoms such as fatigue and weakness. Additional treatment options are based on the patient's serum erythropoietin (EPO) levels.

To know more about myelofibrosis treatment, visit @Myelofibrosis Treatment Guidelines

Myelofibrosis Pipeline Therapies and Key Companies

Momelotinib: Sierra Oncology
Navitoclax: AbbVie
Parsaclisib: Incyte
Reblozyl: Bristol Myers Squibb (Celgene)
Pelabresib: Morphosys
Selinexor: Karyopharm Therapeutics
Zinpentraxin alfa (RG6354): Roche

Learn more about the myelofibrosis therapies in clinical trials @ Drugs for Myelofibrosis Treatment

Myelofibrosis Market Dynamics

The dynamics of the myelofibrosis market are anticipated to change in the coming years owing to the improvement in the research and development activities so that the myelofibrosis market will comprise efficient treatment options. Furthermore, the launch of emerging therapies is also expected to increase the myelofibrosis market size during the forecast period of 2022–2032.

As Myelofibrosis is a rare form of hematologic cancer, companies working on developing their treatment options can make use of several advantages of market exclusivity, premium pricing, trial subsidies, and other benefits from the government bodies for R&D.

Therapy options for patients with comorbidities such as anemia and thrombocytopenia remain an unmet need, but emerging treatments may offer additional benefits for them. JAK inhibitors, the only approved therapy for myelofibrosis, have successfully reduced spleen and symptom burden. However, they do not affect disease progression. Patients who are refractory to JAK inhibition may show survival difficulty.

However, current treatment only provides relief from the signs and symptoms of the disease. A bone marrow transplant being extremely expensive, can be the only treatment option for the disease. Although, the resultant might show negative results on the body. Therefore, bone marrow transplants might not be an option for many people. Around 20% of myelofibrosis patients show minimal or no symptoms, which may pose diagnosis challenges in the myelofibrosis market.

Report Metrics	Details
Study Period	2019–2032
Coverage	7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Base Year	2019
Market CAGR	7.3 %
Market Size in 2021	USD 1,404 million
Key Myelofibrosis Companies	Geron Corporation, AbbVie, Sierra Oncology, Kartos Therapeutics, Menarini Group, Telios Pharma, Novartis Pharmaceuticals, NS Pharma, Karyopharm Therapeutics, Incyte Corporation, Bristol Myers Squibb, MorphoSys, Imago BioSciences, Roche, and others
Key Pipeline Myelofibrosis Therapies	Momelotinib, Navitoclax, Parsaclisib, Reblozyl, Pelabresib, Bomedemstat, Selinexor, Navtemadlin, and others

Scope of the Myelofibrosis Market Report

Therapeutic Assessment: Myelofibrosis current marketed and emerging therapies
Myelofibrosis Market Dynamics: Myelofibrosis market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Myelofibrosis Market Access and Reimbursement

Discover more about drugs for myelofibrosis in development @Myelofibrosis Clinical Trials

Table of Contents

1	Myelofibrosis Key Insights
2	Myelofibrosis Report Introduction
3	Myelofibrosis Market Overview at a Glance
4	Myelofibrosis Executive Summary
5	Myelofibrosis Epidemiology and Market Methodology
6	Myelofibrosis Key Events
7	Myelofibrosis Disease Background and Overview
8	Myelofibrosis Treatment and Management
9	Risk-based Scoring in Myelofibrosis
10	Myelofibrosis Treatment Guidelines
11	Myelofibrosis Epidemiology and Patient Population
11.1	Key Findings
11.2	Assumptions and Rationale
11.3	Total Prevalent Population of Myelofibrosis in the 7MM
11.4	The United States
11.5	EU-5
11.6	Japan
12	Patient Journey
13	Key Endpoints in Myelofibrosis Clinical Trials
14	Myelofibrosis Marketed Drugs
15	Myelofibrosis Emerging Drugs
16	Seven Major Myelofibrosis Market Analysis
16.1	Key Findings
16.2	Market Outlook
16.3	Key Market Forecast Assumptions
16.4	Attribute Analysis
16.5	Total Market Size of Myelofibrosis in the 7MM
16.6	United States Market Size
16.7	EU-5 Market Size
16.8	Japan Market Size
17	Market Access and Reimbursement
18	SWOT Analysis
19	Unmet Needs
20	Appendix
21	DelveInsight Capabilities
22	Disclaimer
23	About DelveInsight

Related Reports

Myelofibrosis Epidemiology Forecast

Myelofibrosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the myelofibrosis epidemiology trends.

Myelofibrosis Pipeline

Myelofibrosis Pipeline Insight – 2022 report provides comprehensive insights about the myelofibrosis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myelofibrosis companies, including Incyte Corporation, Keros Therapeutics, Karyopharm Therapeutics, Celgene Corporation, PharmaEssentia, Novartis, Secura Bio, Pharmaxis, Novartis Oncology, AstraZeneca, Cellenkos, Jacobio Pharmaceuticals, Ohm oncology, among others.

Secondary Myelofibrosis Market

Secondary Myelofibrosis Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key secondary myelofibrosis companies, including Incyte Corporation, Keros Therapeutics, Karyopharm Therapeutics, Celgene Corporation, PharmaEssentia, Novartis, among others.

Primary Myelofibrosis Pipeline

Primary Myelofibrosis Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key primary myelofibrosis companies, including Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, among others.

Primary Myelofibrosis Market

Primary Myelofibrosis Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key primary myelofibrosis companies, including Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, among others.

Post-Polycythemia Vera Myelofibrosis Market

Post-Polycythemia Vera Myelofibrosis Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key post-polycythemia vera myelofibrosis companies, including Sierra Oncology Inc., CTI Biopharma Corp., Incyte Corporation, Imago BioSciences, Inc., Hoffmann-La Roche, among others.

Post-Polycythemia Vera Myelofibrosis Pipeline

Post-Polycythemia Vera Myelofibrosis Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key post-polycythemia vera myelofibrosis companies, including Sierra Oncology Inc., CTI Biopharma Corp., Incyte Corporation, Imago BioSciences, Inc., Hoffmann-La Roche, among others.

Other Trending Reports

Related Healthcare Services

Healthcare Business Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services

Contact Us

Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research LLP